During the last three months, 8 analysts shared their evaluations of Intra-Cellular Therapies (NASDAQ:ITCI), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 4 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 2 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 1 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $85.88, a high estimate of $101.00, and a low estimate of $64.00. Surpassing the previous average price target of $76.75, the current average has increased by 11.9%.
Investigating Analyst Ratings: An Elaborate Study
In examining recent analyst actions, we gain insights into how financial...
ログインすると全部閲覧できます。
ログイン